{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:11Z","timestamp":1791061331470,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>As antibiotic resistance continues to rise, the development of novel <jats:italic>H. pylori<\/jats:italic> treatment regimens, combined with regular assessment of existing treatment regimens, is imperative. The study evaluates the efficacy, safety, and compliance of vonoprazan dual and triple therapy (VDT and VTT) both consisting of vonoprazan 20\u00a0mg twice daily and amoxicillin\/clavulanate 875\u00a0mg\/125 three times daily plus clarithromycin 500\u00a0mg twice daily added in VTT versus standard triple therapy (STT), in which vonoprazan 20\u00a0mg in VTT is replaced by PPI standard or double dose all for 14 days, along with investigating factors influencing compliance, treatment response, and symptoms severity. By per-protocol analysis, the eradication rates of the STT, VDT, and VTT groups were 70%, 76.2%, and 79.2%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.777) indicating suboptimal efficacy of the three treatment regimens. This necessitates the optimization of dosage and frequency of available treatment regimens as well as the development of new regimens with higher eradication rates. Interestingly, the VDT group demonstrated a better safety profile but with no statistically significant difference in cure rate. No difference in compliance with treatment was found between the groups. Gender, frequency of COVID-19 vaccination, height, and BMI were the only factors assessed influencing infection symptoms severity. <\/jats:p>\n          <jats:p>ClinicalTrial.gov ID identifier: NCT05614934, first posted date (07\/11\/2022).<\/jats:p>","DOI":"10.1038\/s41598-025-98606-8","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:53:09Z","timestamp":1746687189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Yumna M.","family":"Shekeban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha A.","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa A.","family":"Header","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwikar M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai M.","family":"Helmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"3","key":"98606_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/1319-3767.54743","volume":"15","author":"BA Salih","year":"2009","unstructured":"Salih, B. A. Helicobacter pylori infection in developing countries: the burden for how long? Saudi J. Gastroenterol. 15(3), 201\u2013207 (2009).","journal-title":"Saudi J. Gastroenterol."},{"issue":"2","key":"98606_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi, J. K. Y. et al. Global prevalence of Helicobacter pylori infection: systematic review and Meta-Analysis. Gastroenterology 153(2), 420\u2013429 (2017).","journal-title":"Gastroenterology"},{"issue":"3","key":"98606_CR3","first-page":"299","volume":"20","author":"RH Hunt","year":"2011","unstructured":"Hunt, R. H. et al. Helicobacter pylori in developing countries. World gastroenterology organisation global guideline. J. Gastrointestin Liver Dis. 20(3), 299\u2013304 (2011).","journal-title":"J. Gastrointestin Liver Dis."},{"issue":"1","key":"98606_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jgh3.12843","volume":"7","author":"N Aumpan","year":"2023","unstructured":"Aumpan, N., Mahachai, V. & Vilaichone, R. Management of Helicobacter pylori infection. JGH Open. 7(1), 3\u201315 (2023).","journal-title":"JGH Open."},{"issue":"5","key":"98606_CR5","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi, A., Carrara, E., Graham, D. Y., Conti, M. & Tacconelli, E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and Meta-analysis in world health organization regions. Gastroenterology 155(5), 1372\u201382e17 (2018).","journal-title":"Gastroenterology"},{"issue":"7","key":"98606_CR6","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(22)62067-5","volume":"162","author":"N Aumpan","year":"2022","unstructured":"Aumpan, N. et al. Tu1079: Predictive factors for successful eradication in patients with Helicobacter pylori treatment failures: a large population-based study. Gastroenterology 162(7), S\u2013874 (2022).","journal-title":"Gastroenterology"},{"issue":"1","key":"98606_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12879-018-3099-4","volume":"18","author":"H Jaka","year":"2018","unstructured":"Jaka, H. et al. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC Infect. Dis. 18(1), 193 (2018).","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"98606_CR8","first-page":"1411","volume":"19","author":"RK Vilaichone","year":"2018","unstructured":"Vilaichone, R. K., Quach, D. T., Yamaoka, Y., Sugano, K. & Mahachai, V. Prevalence and pattern of antibiotic resistant strains of Helicobacter pylori infection in ASEAN. Asian Pac. J. Cancer Prev. 19(5), 1411\u20131413 (2018).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"98606_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ajg.2019.09.001","volume":"20","author":"M Alboraie","year":"2019","unstructured":"Alboraie, M. et al. Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab. J. Gastroenterol. 20(3), 175\u2013179 (2019).","journal-title":"Arab. J. Gastroenterol."},{"issue":"2","key":"98606_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey, W. D., Leontiadis, G. I., Howden, C. W. & Moss, S. F. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 112(2), 212\u2013239 (2017).","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"98606_CR11","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner, P. et al. Management of <\u2009em\u2009>\u2009helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut 71(9), 1724\u20131762 (2022).","journal-title":"Gut"},{"issue":"1","key":"98606_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0889-8553(21)00271-5","volume":"22","author":"BJ Marshall","year":"1993","unstructured":"Marshall, B. J. Treatment strategies for Helicobacter pylori infection. Gastroenterol. Clin. North. Am. 22(1), 183\u2013198 (1993).","journal-title":"Gastroenterol. Clin. North. Am."},{"issue":"6","key":"98606_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/gut.2006.101634","volume":"56","author":"P Malfertheiner","year":"2007","unstructured":"Malfertheiner, P. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 56(6), 772\u2013781 (2007).","journal-title":"Gut"},{"key":"98606_CR14","doi-asserted-by":"crossref","unstructured":"O\u2019Connor, A., Liou, J. M., Gisbert, J. P. & O\u2019Morain, C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter. 24 Suppl 1, e12640 (2019).","DOI":"10.1111\/hel.12640"},{"key":"98606_CR15","doi-asserted-by":"crossref","unstructured":"Olmedo, L. et al. High effectiveness of a 14-Day concomitant therapy for Helicobacter pylori treatment in primary care. An observational multicenter study. J. Clin. Med. 9(8), 2410 (2020).","DOI":"10.3390\/jcm9082410"},{"issue":"11","key":"98606_CR16","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s00535-020-01723-6","volume":"55","author":"H Okubo","year":"2020","unstructured":"Okubo, H. et al. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J. Gastroenterol. 55(11), 1054\u20131061 (2020).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"98606_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12941-018-0281-x","volume":"17","author":"H Tanabe","year":"2018","unstructured":"Tanabe, H. et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann. Clin. Microbiol. Antimicrob. 17(1), 29 (2018).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"16","key":"98606_CR18","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3748\/wjg.v25.i16.1907","volume":"25","author":"S Suzuki","year":"2019","unstructured":"Suzuki, S., Esaki, M., Kusano, C., Ikehara, H. & Gotoda, T. Development of Helicobacter pylori treatment: how do we manage antimicrobial resistance? World J. Gastroenterol. 25(16), 1907\u20131912 (2019).","journal-title":"World J. Gastroenterol."},{"key":"98606_CR19","unstructured":"Dean, A. G. A. T. et al. Epi Info\u2122, a database and statistics program for public health professionals. CDC, Atlanta, GA, USA [ (2011). Available from: www.cdc.gov\/epiinfo"},{"issue":"4","key":"98606_CR20","first-page":"342","volume":"14","author":"H Raina","year":"2021","unstructured":"Raina, H. et al. Efficacy of Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline (LOAD) regimen compared with standard triple therapy to eradicate Helicobacter pylori infection: a prospective randomized study from a tertiary hospital in India. Gastroenterol. Hepatol. Bed Bench. 14(4), 342\u2013348 (2021).","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"issue":"2","key":"98606_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0000000000001719","volume":"57","author":"P Katelaris","year":"2023","unstructured":"Katelaris, P. et al. Helicobacter pylori world gastroenterology organization global guideline. J. Clin. Gastroenterol. 57(2), 111\u2013126 (2023).","journal-title":"J. Clin. Gastroenterol."},{"issue":"16","key":"98606_CR22","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3748\/wjg.v23.i16.2854","volume":"23","author":"N Arslan","year":"2017","unstructured":"Arslan, N., Y\u0131lmaz, \u00d6. & Demiray-G\u00fcrb\u00fcz, E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J. Gastroenterol. 23(16), 2854\u20132869 (2017).","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"98606_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey, W. D. et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the united States and Europe: Randomized clinical trial. Gastroenterology 163(3), 608\u2013619 (2022).","journal-title":"Gastroenterology"},{"issue":"10","key":"98606_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","volume":"2","author":"YT Kuo","year":"2017","unstructured":"Kuo, Y. T. et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2(10), 707\u2013715 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"98606_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"DY Graham","year":"2007","unstructured":"Graham, D. Y., Lu, H. & Yamaoka, Y. A report card to grade Helicobacter pylori therapy. Helicobacter 12(4), 275\u2013278 (2007).","journal-title":"Helicobacter"},{"issue":"9","key":"98606_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami, K. et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65(9), 1439\u20131446 (2016).","journal-title":"Gut"},{"key":"98606_CR27","doi-asserted-by":"publisher","first-page":"4385161","DOI":"10.1155\/2017\/4385161","volume":"2017","author":"M Maruyama","year":"2017","unstructured":"Maruyama, M. et al. Vonoprazan-Based regimen is more useful than PPI-Based one as a First-Line Helicobacter pylori eradication: A randomized controlled trial. Can. J. Gastroenterol. Hepatol. 2017, 4385161 (2017).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"2","key":"98606_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/00365521.2016.1250157","volume":"52","author":"Y Kajihara","year":"2017","unstructured":"Kajihara, Y., Shimoyama, T. & Mizuki, I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand. J. Gastroenterol. 52(2), 238\u2013241 (2017).","journal-title":"Scand. J. Gastroenterol."},{"issue":"10","key":"98606_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/1751-2980.12398","volume":"17","author":"S Shichijo","year":"2016","unstructured":"Shichijo, S. et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. J. Dig. Dis. 17(10), 670\u2013675 (2016).","journal-title":"J. Dig. Dis."},{"issue":"7","key":"98606_CR30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ajg.2016.182","volume":"111","author":"S Suzuki","year":"2016","unstructured":"Suzuki, S., Gotoda, T., Kusano, C., Iwatsuka, K. & Moriyama, M. The efficacy and tolerability of a triple therapy containing a Potassium-Competitive acid blocker compared with a 7-Day PPI-Based Low-Dose clarithromycin triple therapy. Am. J. Gastroenterol. 111(7), 949\u2013956 (2016).","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"98606_CR31","first-page":"169","volume":"9","author":"N Mori","year":"2018","unstructured":"Mori, N. et al. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori. Biomed. Rep. 9(2), 169\u2013174 (2018).","journal-title":"Biomed. Rep."},{"issue":"2","key":"98606_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","volume":"59","author":"S Kiyotoki","year":"2020","unstructured":"Kiyotoki, S., Nishikawa, J. & Sakaida, I. Efficacy of Vonoprazan for Helicobacter pylori eradication. Intern. Med. 59(2), 153\u2013161 (2020).","journal-title":"Intern. Med."},{"issue":"5","key":"98606_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1159\/000501608","volume":"101","author":"T Nishida","year":"2020","unstructured":"Nishida, T. et al. A Triple-Drug Blister-Packaged drug with Vonoprazan improves First-Line eradication of Helicobacter pylori in elderly patients: A retrospective propensity Score-Matched cohort study. Digestion 101(5), 608\u2013614 (2020).","journal-title":"Digestion"},{"issue":"4","key":"98606_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000454762","volume":"94","author":"M Tsujimae","year":"2016","unstructured":"Tsujimae, M. et al. A comparative study of a new class of gastric acid suppressant agent named Vonoparazan versus Esomeprazole for the eradication of Helicobacter pylori. Digestion 94(4), 240\u2013246 (2016).","journal-title":"Digestion"},{"issue":"5","key":"98606_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.kjms.2016.04.009","volume":"32","author":"S Shinozaki","year":"2016","unstructured":"Shinozaki, S. et al. Comparison of Vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J. Med. Sci. 32(5), 255\u2013260 (2016).","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"6","key":"98606_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","volume":"101","author":"T Furuta","year":"2020","unstructured":"Furuta, T. et al. Dual therapy with Vonoprazan and amoxicillin is as effective as triple therapy with Vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion 101(6), 743\u2013751 (2020).","journal-title":"Digestion"},{"issue":"3","key":"98606_CR37","first-page":"301","volume":"69","author":"G Sachs","year":"1996","unstructured":"Sachs, G., Meyer-Rosberg, K., Scott, D. R. & Melchers, K. Acid, protons and Helicobacter pylori. Yale J. Biol. Med. 69(3), 301\u2013316 (1996).","journal-title":"Yale J. Biol. Med."},{"issue":"10","key":"98606_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/BF01963775","volume":"8","author":"ML Grayson","year":"1989","unstructured":"Grayson, M. L., Eliopoulos, G. M., Ferraro, M. J. & Moellering, R. C. Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8(10), 888\u2013889 (1989).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"98606_CR39","doi-asserted-by":"crossref","unstructured":"Scott, D. R., Sachs, G. & Marcus, E. A. The role of acid Inhibition in Helicobacter pylori eradication. F1000Res ;5:F1000 Faculty Rev-1747. (2016).","DOI":"10.12688\/f1000research.8598.1"},{"issue":"1","key":"98606_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/39.1.5","volume":"39","author":"PO Erah","year":"1997","unstructured":"Erah, P. O., Goddard, A. F., Barrett, D. A., Shaw, P. N. & Spiller, R. C. The stability of Amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39(1), 5\u201312 (1997).","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"98606_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1523-5378.1997.tb00076.x","volume":"2","author":"PM Kleveland","year":"1997","unstructured":"Kleveland, P. M., Waldum, H. L., Brenna, E., Aase, S. & Maeland, J. A. Relationship between the efficacy of amoxicillin and intragastric pH for the treatment of Helicobacter pylori infection. Helicobacter 2(3), 144\u2013148 (1997).","journal-title":"Helicobacter"},{"key":"98606_CR42","doi-asserted-by":"publisher","first-page":"1272744","DOI":"10.3389\/fphar.2023.1272744","volume":"14","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, single-center, randomized trial. Front. Pharmacol. 14, 1272744 (2023).","journal-title":"Front. Pharmacol."},{"issue":"3","key":"98606_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2133\/dmpk.20.153","volume":"20","author":"T Furuta","year":"2005","unstructured":"Furuta, T. et al. Influence of CYP2C19 Pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. 20(3), 153\u2013167 (2005).","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"98606_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1067\/mcp.2001.113959","volume":"69","author":"T Furuta","year":"2001","unstructured":"Furuta, T. et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69(3), 158\u2013168 (2001).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"98606_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","volume":"12","author":"M Sugimoto","year":"2007","unstructured":"Sugimoto, M. et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 12(4), 317\u2013323 (2007).","journal-title":"Helicobacter"},{"issue":"12","key":"98606_CR46","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","volume":"47","author":"H Yamasaki","year":"2017","unstructured":"Yamasaki, H. et al. In vitro metabolism of TAK-438, Vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica 47(12), 1027\u20131034 (2017).","journal-title":"Xenobiotica"},{"issue":"6","key":"98606_CR47","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki, S. et al. Seven-day Vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut 69(6), 1019\u20131026 (2020).","journal-title":"Gut"},{"issue":"4","key":"98606_CR48","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3748\/wjg.v23.i4.668","volume":"23","author":"K Sakurai","year":"2017","unstructured":"Sakurai, K. et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J. Gastroenterol. 23(4), 668\u2013675 (2017).","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"98606_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","volume":"44","author":"S Zhou","year":"2005","unstructured":"Zhou, S. et al. Mechanism-based Inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44(3), 279\u2013304 (2005).","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"98606_CR50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2165\/00003088-200746120-00004","volume":"46","author":"S Eberl","year":"2007","unstructured":"Eberl, S. et al. Role of p-glycoprotein Inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46(12), 1039\u20131049 (2007).","journal-title":"Clin. Pharmacokinet."},{"key":"98606_CR51","first-page":"1","volume-title":"xPharm: the Comprehensive Pharmacology Reference","author":"E Scholar","year":"2007","unstructured":"Scholar, E. Clarithromycin. In xPharm: the Comprehensive Pharmacology Reference (eds Enna, S. J. & Bylund, D. B.) 1\u20136 (Elsevier, 2007)."},{"issue":"6","key":"98606_CR52","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1046\/j.1365-2125.2002.01604.x","volume":"53","author":"SI Hamdy","year":"2002","unstructured":"Hamdy, S. I. et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 53(6), 596\u2013603 (2002).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"98606_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","volume":"22","author":"SA Scott","year":"2012","unstructured":"Scott, S. A. et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 22(2), 159\u2013165 (2012).","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"98606_CR54","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","volume":"118","author":"HS Qian","year":"2023","unstructured":"Qian, H. S. et al. Ten-Day Vonoprazan-Amoxicillin dual therapy as a First-Line treatment of Helicobacter pylori infection compared with Bismuth-Containing quadruple therapy. Am. J. Gastroenterol. 118(4), 627\u2013634 (2023).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"98606_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejmhg.2013.03.004","volume":"14","author":"MS Fathi","year":"2013","unstructured":"Fathi, M. S., El-Folly, R. F., Hassan, R. A. & El-Arab, M. E. Genotypic and phenotypic patterns of antimicrobial susceptibility of Helicobacter pylori strains among Egyptian patients. Egypt. J. Med. Hum. Genet. 14(3), 235\u2013246 (2013).","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"98606_CR56","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.2147\/IDR.S386082","volume":"15","author":"M Metwally","year":"2022","unstructured":"Metwally, M., Ragab, R., Abdel Hamid, H. S., Emara, N. & Elkholy, H. Helicobacter pylori antibiotic resistance in Egypt: A Single-Center study. Infect. Drug Resist. 15, 5905\u20135913 (2022).","journal-title":"Infect. Drug Resist."},{"issue":"null","key":"98606_CR57","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2147\/IDR.S250200","volume":"13","author":"GG Kasahun","year":"2020","unstructured":"Kasahun, G. G., Demoz, G. T. & Desta, D. M. Primary resistance pattern of Helicobacter pylori to antibiotics in adult population: A systematic review. Infect. Drug Resist. 13 (null), 1567\u20131573 (2020).","journal-title":"Infect. Drug Resist."},{"issue":"7","key":"98606_CR58","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins, H. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 41(7), 636\u2013648 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"98606_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1046\/j.1525-1497.2001.016004266.x","volume":"16","author":"AJ Barsky","year":"2001","unstructured":"Barsky, A. J., Peekna, H. M. & Borus, J. F. Somatic symptom reporting in women and men. J. Gen. Intern. Med. 16(4), 266\u2013275 (2001).","journal-title":"J. Gen. Intern. Med."},{"key":"98606_CR60","doi-asserted-by":"publisher","first-page":"8320496","DOI":"10.1155\/2017\/8320496","volume":"2017","author":"HR Ghasemi Basir","year":"2017","unstructured":"Ghasemi Basir, H. R., Ghobakhlou, M., Akbari, P., Dehghan, A. & Seif Rabiei, M. A. Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis. Gastroenterol. Res. Pract. 2017, 8320496 (2017).","journal-title":"Gastroenterol. Res. Pract."},{"issue":"3","key":"98606_CR61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1620\/tjem.2022.J043","volume":"257","author":"T Akaishi","year":"2022","unstructured":"Akaishi, T. et al. Prolonged diarrhea following COVID-19 vaccination: A case report and literature review. Tohoku J. Exp. Med. 257(3), 251\u2013259 (2022).","journal-title":"Tohoku J. Exp. Med."},{"key":"98606_CR62","first-page":"9989515","volume":"2023","author":"M Hasanzarrini","year":"2023","unstructured":"Hasanzarrini, M., Salehi, A. M. & Nirumandi Jahromi, S. Development of peptic ulcer following second shot of sputnik V vaccine: A case report and literature review of rare side effects of sputnik V vaccine. Case Rep. Infect. Dis. 2023, 9989515 (2023).","journal-title":"Case Rep. Infect. Dis."},{"issue":"11","key":"98606_CR63","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s00464-002-8701-5","volume":"17","author":"A Foster","year":"2003","unstructured":"Foster, A., Richards, W. O., McDowell, J., Laws, H. L. & Clements, R. H. Gastrointestinal symptoms are more intense in morbidly obese patients. Surg. Endosc. 17(11), 1766\u20131768 (2003).","journal-title":"Surg. Endosc"},{"issue":"02","key":"98606_CR64","first-page":"168","volume":"40","author":"HSH Al-Khalidy","year":"2021","unstructured":"Al-Khalidy, H. S. H. Obesity and helicobacter pylori infection in adults with Non specific colitis. J. Coloproctology. 40(02), 168\u2013171 (2021).","journal-title":"J. Coloproctology"},{"issue":"9","key":"98606_CR65","first-page":"344","volume":"63","author":"RJ Loffeld","year":"2005","unstructured":"Loffeld, R. J. Helicobacter pylori, obesity and gastro-oesophageal reflux disease. Is there a relation? A personal view. Neth. J. Med. 63(9), 344\u2013347 (2005).","journal-title":"Neth. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98606-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T19:02:57Z","timestamp":1746730977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98606-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98606"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98606-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was conducted following the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice and was approved by the Ethics Committee of Alexandria University (serial number: 0107175).\u00a0All study participants were informed about the nature, goal, and potential risks as well as adverse effects of the study and provided their written, informed consent before study entry.\u00a0The study was registered at the Clinical Trials.gov Protocol Registration and Results System () with the trial registration number NCT05614934, first posted date (07\/11\/2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"15989"}}